Drugs in R&D is a peer-reviewed english-language open-access journal published by Adis, Springer Healthcare in United Kingdom, operating under an open-access model since 2010. The journal covers Therapeutics. Pharmacology.
Authors are required to pay an article processing charge to publish in Drugs in R&D; refer to the journal's APC page for the current rate. A waiver policy is offered for eligible authors. Articles are released under the CC BY-NC license (see other journals using this license).
To date, Drugs in R&D has published 1,354 articles. Articles are minted with DOIs through the prefix 10.2165. All submissions undergo plagiarism screening before peer review.
Keywords
pharmacology, drug development
At a glance
- Publisher
- Adis, Springer Healthcare
- Country
- United Kingdom
- Primary language
- English
- License
- CC BY-NC
- Peer review
- Anonymous peer review
- OA since
- 2010
- Review time
- 8 weeks
- DOI prefix
10.2165- Plagiarism check
- Yes
ISSN
- 1174-5886
- electronic
- 1179-6901
Frequently asked questions
Is Drugs in R&D peer-reviewed?
Yes — Drugs in R&D operates a Anonymous peer review review process.
Does Drugs in R&D charge an article processing charge (APC)?
Yes — refer to the journal's APC page for the current rate. A waiver policy is available for eligible authors.
What subjects does Drugs in R&D publish?
Drugs in R&D publishes research in Therapeutics. Pharmacology.
What languages does Drugs in R&D accept?
Drugs in R&D accepts manuscripts in English.
What is the ISSN of Drugs in R&D?
ISSN:
1174-5886 (print) · 1179-6901 (electronic).How do I submit a manuscript to Drugs in R&D?
Submit through the journal's official portal: visit submission page →
How long does peer review take at Drugs in R&D?
Average time from submission to publication is approximately 8 weeks.